Renin: friend or foe?

被引:72
作者
Brown, Morris J. [1 ]
机构
[1] Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England
关键词
D O I
10.1136/hrt.2006.107706
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renin maintains blood pressure through vasoconstriction when there is inadequate salt to maintain volume. In populations where blood pressure is more often high than low, and vascular death more common than haemorrhage or dehydration, therapeutic reductions in renin secretion or response are valuable. Whether long- term benefits are due entirely to blood pressure reduction remains unproved. The pathway can be blocked at its rate- limiting step ( beta blockade or direct renin inhibition), the synthesis of the active product, angiotensin II, or at the receptor for angiotensin. Because renin and sodium are the two main factors in blood pressure control, and renin levels vary inversely with sodium load, blood pressure control requires a combination of natriuresis and blocking the consequential increase in renin activity. Being a large and stable molecule, renin is among the easiest and cheapest of hormone measurements. Understanding the simple biochemistry and physiology of renin permits optimal use of the drugs acting to raise or suppress this hormone.
引用
收藏
页码:1026 / 1033
页数:8
相关论文
共 82 条
[1]  
Agodoa L, 2007, J HYPERTENS, V25, P951
[2]   Plasma renin activity levels in hypertensive persons: Their wide range and lack of suppression in diabetic and in most elderly patients [J].
Alderman, MH ;
Cohen, HW ;
Sealey, JE ;
Laragh, JH .
AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (01) :1-7
[3]  
[Anonymous], 2002, JAMA
[4]   Additive effects of losartan and enalapril on blood pressure and plasma active renin [J].
Azizi, M ;
Guyene, TT ;
Chatellier, G ;
Wargon, M ;
Menard, J .
HYPERTENSION, 1997, 29 (02) :634-640
[5]   Renin inhibition with aliskiren: where are we now, and where are we going? [J].
Azizi, M ;
Webb, R ;
Nussberger, J ;
Hollenberg, NK .
JOURNAL OF HYPERTENSION, 2006, 24 (02) :243-256
[6]   CHANGES IN THE RENIN-ANGIOTENSIN-ALDOSTERONE AXIS IN LATER LIFE [J].
BELMIN, J ;
LEVY, BI ;
MICHEL, JB .
DRUGS & AGING, 1994, 5 (05) :391-400
[7]   β-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects [J].
Blumenfeld, JD ;
Sealey, JE ;
Mann, SJ ;
Bragat, A ;
Marion, R ;
Pecker, MS ;
Sotelo, J ;
August, P ;
Pickering, TG ;
Laragh, JH .
AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (05) :451-459
[8]  
BRAWN MJ, 2006, BMJ-BRIT MED J, V332, P833
[9]   The renin-angiotensin-aidosterone system: Cardiorenal effects and implications for renal and cardiovascular disease states [J].
Brewster, UC ;
Setaro, JF ;
Perazella, MA .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2003, 326 (01) :15-24
[10]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372